TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04230278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START-Play Physical Therapy
Description: Physical Therapy focused on movement and cognitive skills at the same time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Physical Therapy
Description: Physical Therapy focused on movement and reducing impairments
Study: NCT05039892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D185
Description: All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.
Study: NCT05259280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellinks
Description: Digital health and virtual care program for COPD management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellinks
Description: Digital health and virtual care program for COPD management.
Study: NCT06101589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 hydroxy cholecalciferol (Vitamin D) /25(OH)D3.
Description: 5 mg (200,000 IU) vitamin D3 in 1 ml ethyl oleate Pharmaceutical form: Solution of vitamin D3 in ethyl oleate, 0.75% w/v. three doses will be given orally every a month apart.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil in 1 ml ethyl oleate with no vitamin D3 content
Study: NCT05243511

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital ACT
Description: Participants in this arm receive Digital ACT as well as standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Symptom Tracker
Description: Participants in this arm complete a digital symptom and function tracker and monitor, are provided access to digital fibromyalgia and health education, and receive standard of care.
Study: NCT05461534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness yoga
Description: Each mindfulness yoga session will last for 90 minutes and will be conducted in a group format once a week. Each session includes breathing exercise (10 min), mindfulness meditation and body scan (20 min) and yoga practice (60 min).
Study: NCT06516094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib+Pregabalin+Vitamin B fixed dose
Description: One tablet of 200 mg / 150 mg / 100 mg / 50 mg / 0.50 mg + 1 capsule of placebo once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib + Vitamin B fixed dose
Description: One capsule of 200 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin + Vitamin B fixed dose
Description: One capsule of 150 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
Study: NCT04875143

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus aurantium L.
Description: In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Citrus aurantium L.
Description: In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
Study: NCT06118398

Intervention type: DRUG
Intervention: Intravenous methylprednisolone (IVMP) and Efgartigimod
Description: IVMP 800-1000mg/day for 3-5 days plus Efgartigimod (Efgartigimod: 10mg/kg IV on Day 1, Day 8, Day 15 and Day 22 after IVMP.)

Intervention type: DRUG
Intervention: IVMP
Description: IVMP 800-1000mg/day for 3-5 days.
Study: NCT06025968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-CBT
Description: The content is based on manual by Perlis et al (2015) and has slightly reworked by the research team by shortening treatment from seven to six sessions and allowing for day-time naps that may be necessary for patient with MS (Siengsukon et al. 2020). Due to the high prevalence of fatigue in people with MS, naps during the day may be a necessity to cope with everyday tasks. In cases where patients could not refrain from naps, they were advised to limit them to maximum 20 minutes and to take them as early in the day as possible. Other components are sleep restriction, sleep hygiene, stimulus control and cognitive techniques..

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied relaxation
Description: Treatment consits of 6 modules. The main components in the training program will be progressive muscle relaxation, short relaxation with release only and without tension, and finally the participants will be taught rapid relaxation.
Study: NCT04969302

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: The primary outcome of this study was SSI within 30 days of surgery, as defined by the Centers for Disease Control and Prevention. Secondary outcomes were identification of the causative organism, and investigation of clinical factors such as body mass index (BMI), operation time, days of hospitalization, etc. that may be associated with SSI.~All patients were followed up for SSI until discharge from hospital and at the outpatient visits. SSI surveillance data forms were used for the collection of primary and secondary outcome data.~SSI rates and distribution of identified micro-organisms for each group will measured
Study: NCT05097963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound Shear Wave Elastography
Description: Software to determine stiffness of liver for evaluating liver fibrosis.
Study: NCT05341141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frozen glove and sock
Description: Preparation of frozen glove and sock: 4℃ for 3 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: ddEC-ddT
Description: Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ddEC-ddT
Description: Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.
Study: NCT04962308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Inactivated Vaccine
Description: 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Inactivated Vaccine
Description: 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The SARS-CoV-2 Inactivated Vaccine
Description: 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
Study: NCT06212336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Interventional Medicinal Product (IMP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Interventional Medicinal Product (IMP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Control arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Control arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Control arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Interventional Medicinal Product (IMP)
Study: NCT05756959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBM
Description: PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBM
Description: PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral defocus spectacles
Description: plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral defocus spectacles
Description: plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single vision spectacles
Description: Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision spectacles
Description: Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
Study: NCT05666167

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Telehealth Exercise Sessions with text messaging plus booster sessions
Description: Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Telehealth Exercise Sessions with text messaging plus booster sessions
Description: Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.
Study: NCT06514768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JY231
Description: Infusion of JY231 Injection by dose of 1-10×10\^6 Transduction Units(TU)/ kg、1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg. Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
Study: NCT05945537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-822 (A)
Description: Different dose levels of INI-822

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (B)
Description: Matching placebo to INI-822
Study: NCT05452343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: 600 mg (first doing) + 300 mg (subsequent dosing), once every two weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CM310
Description: 600 mg (first doing) + 300 mg (subsequent dosing), once every two weeks
Study: NCT06518746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryopreservation of gonadal tissue
Description: Patients at risk for primary gonadal tumors will undergo unilateral or bilateral gonadectomy for clinical purposes as a standard of care, and a portion of the surgically removed tissue will be cryopreserved for fertility preservation. The pathologist will assess the tissue using sterile technique and every other section will undergo histologic analysis, including evaluation for the presence of tumor or viable germ cell elements. The sections of the tissue for fertility preservation will be refrigerated and held until a final diagnosis is made on the tissue sections that are being processed for histologic analysis. If no tumor is identified and viable germ cell elements are identified, the tissue sections allotted for preservation will be sent in holding media for processing and cryopreservation.
Study: NCT05014087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous digoxin
Description: Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial.~Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing.~Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed.
Study: NCT06067152

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EIT measurement
Description: Evaluation of mechanical ventilation and ventilation distribution through EIT. Mechanical ventilation is set by the physician according to clinical protocolized criteria

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staircase Recruitment Maneuvers with EIT guided and decremental PEEP trial
Description: SRMs will be performed with a standardized ventilation protocol. Patient will be sedated, paralyzed and ventilated in pressure controlled mode, FIO2 to obtain SPO2\> 92%, RR 25, I:E =1:1.5. Alarm of pressure limit will be set at 35 cmH2O. The ventilator will be equipped with inspiratory and expiratory hold taste. Inspiratory and expiratory occlusion will be held for 5 seconds, data will be stored and analyzed with the ventilator own tool.~Decremental PEEP trial will start if plateau pressure 30 cmH2O will be reached or end inspiratory transpulmonary pressure will exceed 28 cmH2O value. Once reached this level of plateau or transpulmonary pressure, PEEP will be reduced in three steps from 12, 10 and finally to 8 cmH2O every 20 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Setting of EIT-guided mechanical ventilation
Description: Mechanical ventilation is set according to EIT measurement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reevaluation after 24 h
Description: Evaluation of mechanical ventilation and ventilation distribution through EIT after 24h of ventilation EIT-guided
Study: NCT05406635

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biomarkers: Troponins and natriuretic peptides
Description: Biomarker monitored treatment with measurement of NT-proBNP and cTNT / TNI in weeks 0, 9, 18, 30 and 48 of the treatment period.
Study: NCT06297811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib Injection
Description: Experimental: trilaciclib group Intervention: Drug: Trilaciclib Injection \[Cosela\] 240 mg/m\^2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Drug: Paclitaxel 175 mg/m\^2, intravenous drip over ≥ 3 hours , d1, Q3W, at least 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Drug: Paclitaxel 175 mg/m\^2, intravenous drip over ≥ 3 hours , d1, Q3W, at least 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: area under curve(AUC) 5\~6, intravenous drip over ≥ 1 hours, d1, Q3W, at least 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: area under curve(AUC) 5\~6, intravenous drip over ≥ 1 hours, d1, Q3W, at least 6 cycles.
Study: NCT05865119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTIMUS covered stent
Description: The procedure involves placement of a long and large balloon-expandable covered stent in the superior vena cava that tunnels the abnormal pulmonary venous return to the left atrium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical correction of a SVD
Description: Under cardiopulmonary bypass and open heart surgery, surgical correction of SVD either using single patch, double patch or Warden techniques
Study: NCT05653076

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa extract
Description: Daily supplementation with 520 mg of Hibiscus sabdariffa extract for 10 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hibiscus sabdariffa extract
Description: Daily supplementation with 520 mg of Hibiscus sabdariffa extract for 10 days.
Study: NCT05585606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume Matched Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scp776 (1.9 mg/kg)
Description: Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 1.9 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scp776 (3.8 mg/kg)
Description: Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 3.8 mg/kg
Study: NCT06383728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma will receive Osimertinib ( 80mg/d, ≥9 weeks).
Study: NCT06230237

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smiling is fun + professional support
Description: Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.~While they do the online program, they will receive periodically professional support. The professional support will be contacts of 20 minutes long, will take place every two weeks and will last 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smiling is fun
Description: Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.
Study: NCT06514014

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preterm Infant Formula
Description: Transition from donor human milk to preterm infant formula
Study: NCT05039983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EGCG
Description: EGCG use various concentrations dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 30 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls.
Study: NCT05427188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress paradigm
Description: HV will receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham paradigm
Description: HV will receive mental arithmetic challenges where threat components from the program and/or the investigator are absent
Study: NCT05847816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group: infrared vascular imaging
Description: Experimental group - infrared vascular imaging;Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - isometric hand exercise; Stress balls will be given to patients 10 minutes before the PIVC procedure and they will be asked to perform hand-clamping exercises with both hands. Processing will then begin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group: infrared vascular imaging
Description: Experimental group - infrared vascular imaging;Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - isometric hand exercise; Stress balls will be given to patients 10 minutes before the PIVC procedure and they will be asked to perform hand-clamping exercises with both hands. Processing will then begin.
Study: NCT06344221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dextrain Manipulandum and haptic feedback device
Description: Assessment of key components of manual dexterity in addition to vibrotactile stimulation on the fingers and wrist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dextrain Manipulandum and haptic feedback device
Description: Assessment of key components of manual dexterity in addition to vibrotactile stimulation on the fingers and wrist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dextrain Manipulandum and haptic feedback device
Description: Assessment of key components of manual dexterity in addition to vibrotactile stimulation on the fingers and wrist.
Study: NCT06127849

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training + Placebo (Capsule) + Placebo (Sachet)
Description: * Placebo sachet of 20 gms dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One Placebo capsule to be taken 30 minutes after sachet in the morning.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training + Whey protein (40 gms) + Placebo (Capsule)
Description: A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~- One Placebo capsule to be taken 30 minutes after whey protein in the morning

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)
Description: * A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One capsule of EB-PA to be taken 30 minutes after whey protein in the morning
Study: NCT05682196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab added to standard of care treatment
Description: Rituximab with standard of care treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care treatment alone
Description: Standard of care treatment alone
Study: NCT06371781

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum Netrin-4, Resistin and Sfrp-5 level measurement
Description: Measurements of the levels of these molecules in the serum samples of the study group will be done with the ELISA kit.
Study: NCT05846854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment for bleeding disorder with tailored post-operative care
Description: Intervention will be expanded lab work-up for hematologic conditions, consultation by Hematology and tailored intra-operative and post-operative plan with aim to mitigate bleeding and hemorrhage risk, balancing thrombotic risk with this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment for bleeding disorder with tailored post-operative care
Description: Intervention will be expanded lab work-up for hematologic conditions, consultation by Hematology and tailored intra-operative and post-operative plan with aim to mitigate bleeding and hemorrhage risk, balancing thrombotic risk with this intervention.